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Background: The ATP7A gene encodes the ATP7A protein, which is a trans-Golgi network copper transporter
expressed in the brain and other organs. Mutations in this gene cause disorders of copper metabolism, such as
Menkes disease. Here we describe the novel and unusual mutation (p.T1048I) in the ATP7A gene of a child with
Menkes disease. The mutation affects a conserved DKTGT1048 phosphorylation motif that is involved in the catalytic
activity of ATP7A. We also describe the clinical course and the response to copper treatment in this patient.
Case presentation: An 11-month-old male Caucasian infant was studied because of hypotonia, ataxia and global
developmental delay. The patient presented low levels of serum copper and ceruloplasmin, and was shown to be
hemizygous for the p.T1048I mutation in ATP7A. The diagnosis was confirmed when the patient was 18 months
old, and treatment with copper-histidinate (Cu-His) was started immediately. The patient showed some neurological
improvement and he is currently 8 years old. Because the p.T1048I mutation affects its catalytic site, we expected a
complete loss of functional ATP7A and a classical Menkes disease presentation. However, the clinical course of the
patient was mild, and he responded to Cu-His treatment, which suggests that this mutation leads to partial
conservation of the activity of ATP7A.
Conclusion: This case emphasizes the important correlation between genotype and phenotype in patients with
Menkes disease. The prognosis in Menkes disease is associated with early detection, early initiation of treatment and
with the preservation of some ATP7A activity, which is necessary for Cu-His treatment response. The description of
this new mutation and the response of the patient to Cu-His treatment will contribute to the growing body of
knowledge about treatment response in Menkes disease.
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Menkes disease (MD) (OMIM #309400) is an X-linked
recessive disorder of copper metabolism; it is caused by
mutations in the ATP7A gene [1]. There are several clin-
ical variants of MD: classical MD (90–95% of patients),
mild MD, occipital horn syndrome [2] and a new syn-
drome characterized by isolated distal motor neur-
opathy, no signs of copper deficiency and adult onset
[3]. Classic MD is characterized by neonatal neurological
degeneration, coarse and twisted hair, hypopigmentation
and seizures; death usually occurs by the age of three
years [2]. Mild MD is a moderate form of the disease, in* Correspondence: ibaeza@encb.ipn.mx
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distribution, and reproduction in any mediumwhich cerebellar ataxia and moderate developmental
delay predominate [4]. Occipital horn syndrome is the
mildest form of MD and is characterized by connective
tissue abnormalities and some neurological alterations
[2]; in this form of the disease, the ATP7A protein
retains some of its activity [5,6].
The ATP7A gene encodes a transmembrane P-type
ATPase that delivers copper to copper-dependent
enzymes in the trans-Golgi network (TGN). The P-type
ATPases ATP7A and ATP7B are membrane proteins
that hydrolyse ATP for the active transport of cations
across cellular membranes, forming acyl-phosphate
intermediates [7]. The loss of ATP7B function causes
Wilson’s disease [8], while mutations that eliminate or
reduce the activity of ATP7A cause MD. ATP7A resides
in the TGN but it can relocate to the basolateralntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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extracellular copper concentrations [9]; this protein con-
tains an N-terminal tail with six metal-binding sites,
eight transmembrane segments, an ATP-binding do-
main, an A-domain, and a C-terminal tail. The metal-
binding sites accept copper from cytoplasmic carriers
and deliver it to the channel formed by the transmem-
brane segments for its transport across the membrane
into the TGN. The ATP-binding domain contains a
nucleotide-binding motif (N-domain) and a phosphoryl-
ation motif (P-domain); the phosphorylation motif
(DKTGT) starts on the 1044 aspartate residue (D1044)
[7], it is conserved in all P-type ATPases [10] and parti-
cipates in the catalytic reaction as the acyl-phosphate
intermediate. The A-domain is a phosphatase that hy-
drolyses the acyl-phosphate after copper transport [7,11]
(Figure 1A). In this study, we report a mutation that
affects the phosphorylation motif (DKTGT1048) of
human ATP7A in an infant with MD; this mutation
involves the substitution of the 1048 threonine residue
with an isoleucine residue (p.T1048I). We also describe
the clinical course and the response to copper treatment
in this patient.
Case presentation
An 11-month-old male Caucasian infant was referred to the
Hospital of Lanzarote as a result of hypotonia (which was
observed soon after his birth), ataxia, global developmental
delay and clonic seizures. The infant was born after an un-
complicated full-term pregnancy, with a birth weight of
2.5 kg. At the time of examination, he presented psycho-
motor retardation, hair changes (scarce, thin, coarse), severe
head lag and inability to sit independently. The serum con-
centrations of glucose, urea nitrogen, creatinine, lactate, K+,
Na+, Cl-, Ca2+ Mg2+, phosphorus, liver enzymes, pancreatic
amylase, total cholesterol, HDL, LDL, triglycerides and total
protein were normal. A diagnosis of MD was suggested by
the clinical features of the patient; this diagnosis was sup-
ported by reduced levels of copper (38 μg/dl) and cerulo-
plasmin (12 mg/dl) in serum (normal range, 90–190 μg/dl
and 20–60 mg/dl, respectively), and by copper accumulation
(determined by atomic absorption spectroscopy) in fibro-
blasts obtained from the patient and cultured in vitro
(227 ng/mg protein; normal range, 21–46 ng/mg). The
patient’s mother and grandmother had normal copper and
ceruloplasmin serum levels (Figure 1B).
The patient’s family history was not suggestive of an
X-linked disorder; however, his mother had a previous
spontaneous abortion. Mutation analysis of the ATP7A
gene (which is found on chromosome Xq13.2-q13.3) by
PCR and DNA sequencing showed that the patient and
his mother carried a point mutation in the 16th exon of
this gene: a change of C for T (c.3288 C>T), which
results in the replacement of the 1048 threonine residuewith an isoleucine residue [12,13] (Figure 2B). A specific
restriction fragment length polymorphism (RFLP) assay
using HinfI corroborated the presence of the p.T1048I
mutation in the patient and in his mother, but not in his
grandmother (Figure 2A).
Treatment with 100 μg/kg/day of copper-histidinate
(Cu-His) (Carreras Pharmaceutical Laboratories, Barcelona,
Spain) was initiated when the patient was 18 months old
and was maintained for 6.5 years. Cu-His treatment was
suspended when an increased β-2 microglobulin concentra-
tion was found in the patient’s urine; nephrotoxicity caused
by copper treatments is usually reversible [14]. The Cu-His
treatment increased copper and ceruloplasmin serum levels
to normal values (102 μg/dl and 28 mg/dl, respectively) after
three years. Currently, the patient is 8 years old; his hair
characteristics and muscular tone have improved, and the
frequency of his seizures has decreased. Some partial
ATP7A activity is necessary to achieve a response to Cu-His
treatment in MD [14]. The mild phenotype presented by
this patient and his long survival, together with his response
to Cu-His treatment, suggest that the p.T1048I mutation
causes only a partial loss of ATP7A function, which prob-
ably does not completely block copper transport across the
blood–brain barrier and therefore results in moderate
neurological impairment.
Only one other mutation in the DKTGT1048 motif has
been reported: it involves the substitution of the 1044
aspartate residue with a glycine residue (p.D1044G), and
it was identified in a patient with classic MD [15]; this
mutation completely eliminates ATP7A activity. In
ATP7B, the mutation of D1027 (the residue analogue to
D1044) prevents the formation of the acyl-phosphate
intermediate, and is associated with a complete loss of
the copper-transport activity of ATP7B in Wilson’s
disease [16,17]. ATP7A mutations in K1045, T1046 or
G1047 have not been identified in MD patients; however,
directed mutagenesis studies with P-type ATPases report
that mutations in analogous residues decreased the affin-
ity of the P-domain for ATP and disrupted the formation
of acyl-phosphate [18,19]. Molecular-modelling analysis
of ATP bound to the N-domain of ATP7B [20], to the
P-domain of Ca2+ ATPase and to CopA (a bacterial
orthologous Cu+-transporting P-type ATPase) [21,22],
suggests that the D1044, K1045 and T1046 residues of
the P-domain of ATP7A may form hydrogen bonds with
the phosphate tail of ATP. The analyses also rule out the
participation of the T1048 residue of ATP7A in these
hydrogen bonds with ATP, but T1048 could still form
hydrogen bonds with amino acid residues in the N- and
A-domains of ATP7A.
In the case of p.T1048I (the mutation reported in this
study), the replacement of the 1048 threonine residue
with isoleucine, an amino acid of different size, charge
and hydrophobicity, could alter the interactions between
Figure 1 A) Transmembrane organization of the human ATP7A protein. This schematic representation is based on structural studies of
ATP7A [7]. ATP7A contains five regions: i) an N-terminal tail with six metal-binding sites (MBS 1–6), ii) eight trans-membrane segments (TMS), iii)
an ATP-binding domain that contains a nucleotide-binding motif (N-domain) and a phosphorylation motif (P-domain, DKTGT1048), iv) an A-
domain and v) a C-terminal tail. B) Presence of ATP7A gene mutation (c.3288 C> T), and copper, ceruloplasmin and β-2 microglobulin levels in
the patient and in members of his family. The patient’s serum levels of copper and ceruloplasmin were measured while he was receiving Cu-His
(100 μg/kg/day). The urine level of β-2 microglobulin was determined 6.5 years after the administration of Cu-His (normal range, 30–370 μg/24 h).
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inadequate folding that could affect the formation of the
acyl-phosphate intermediate. This altered enzymatic
activity may interfere with the copper-induced re-
localization of ATP7A from the TGN to the plasma
membrane, affecting copper transport and leading to
mild MD. This conclusion is supported by mutations of
an analogous residue (T1031) in ATP7B, which affect
copper transport and are found in patients with Wilson’s
disease [23-25]. According to the studies cited above,
and to the characteristics of the mutation reported in
this study, we propose that mutations in amino acid resi-
dues that are involved directly in the attachment and hy-
drolysis of ATP, in the formation and hydrolysis of acyl-phosphate and in the attachment of copper (such as
D1044, K1045, T1046 and G1047) may cause a complete
loss of functional ATP7A and result in classical MD. In
contrast, mutations in amino acid residues that are not
involved in these processes (such as T1048) may cause
only a partial loss of function.
Treatment with Cu-His did not completely normalize
the neurological manifestations in our patient, but some
of them did improve. His epilepsy pattern is multifocal
and myoclonic, as was previously reported for MD
patients with this age [26,27]. We observed a decrease in
the frequency of seizures and ataxic movements, and an
increase in motor activities and muscle tone, (which
increased from a score of 2 to 3 of a maximum of 5 in
Figure 2 A) Restriction fragment length polymorphism (RFLP) assay. Exon 16 of the ATP7A gene was amplified using specific primers, and
the PCR product was digested with HinfI. The c.3288 C > T mutation introduces a HinfI restriction site that divides the 107 bp fragment into two
fragments of 79 and 28 bp. ud PCR, undigested PCR. B) DNA sequence of part of the ATP7A gene (exon 16) from the patient and from a normal
control; the mutation is shown in red.
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nificant improvements in the patient’s cognitive and psy-
chosocial functions, but the patient does not speak and
he attends a special school for children with different
capabilities. The Cu-His treatment was initiated as soon
as the diagnosis was confirmed, and by then the patient
was 18 months old. In most cases, the neurological
improvements of patients with MD that start their treat-
ment so long after birth are poor [28]; however, it is ad-
visable to administer the copper treatment anyway,
because it prolongs survival, reduces the frequency of
seizures and improves the patient’s quality of life [29,30].
Conclusion
The p.T1048I mutation, which affects the conserved
DKTGT1048 phosphorylation motif of ATP7A, probably
causes a partial loss of the function of this protein. The
residual activity of ATP7A allowed a response to Cu-His
treatment in this patient; and although the treatment
was started when the patient was 18 months old, it has
led to the patient's long survival. This case emphasizes
the important correlation between genotype and re-
sponse to Cu-His treatment in patients with MD. The
prognosis in these patients is associated with an early
detection of the disease (ideally through detailed new-
born screening) and an immediate initiation of Cu-His
treatment in eligible patients, before the occurrence of
irreversible neurodegeneration.Abbreviations
Cu-His: Copper-histidinate; MD: Menkes disease; PCR: Polymerase chain
reaction; RFLP: Restriction fragment length polymorphism; TGN: Trans-Golgi
network.
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